[Treatment of primary chronic polyarthritis with ranoroc (author's transl)].
In the framework of a clinical study the butazone derivative Ranoroc was tested for efficacy and tolerance in 50 patients with primary chronic polyarthritis. The success rates both in previously treated and untreated patients were approximately equal, i. e. 92%. In the previously treated group, a superior effect of Ranoroc as compared with the earlier treatment was stated by the patients in 57% and by the physician in about 36% of the cases. The tolerance was very good. Nausea and heartburn occurred in 3 cases only and were controlled by reducing the dosage. Discontinuation of the trial was required in two cases on account of skin allergies. The continuously monitored laboratory parameters gave no evidence whatsoever of a negative influence, so that even a longterm treatment with Ranoroc seems possible.
D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004338:Drug Combinations; D004341:Drug Evaluation; D005069:Evaluation Studies as Topic; D006801:Humans; D010653:Phenylbutazone / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D004338:Drug Combinations; D010653:Phenylbutazone
Zur Behandlung der primär chronischen Polyarthritis mit Ranoroc.